TRex Bio (NASDAQ:TRXB) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a report issued on Tuesday, MarketBeat Ratings reports. The firm issued an overweight rating on the stock.

A number of other analysts have also recently issued reports on TRXB. Stifel Nicolaus initiated coverage on TRex Bio in a research report on Tuesday. They issued a “buy” rating and a $39.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on TRex Bio in a research note on Tuesday. They set an “overweight” rating and a $20.00 target price for the company. Finally, Wedbush initiated coverage on TRex Bio in a report on Monday. They set an “outperform” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $29.67.

TRex Bio Price Performance

Shares of NASDAQ TRXB opened at $12.99 on Tuesday. TRex Bio has a twelve month low of $12.50 and a twelve month high of $16.56.

Insiders Place Their Bets

In related news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the stock in a transaction on Tuesday, October 13th. The shares were purchased at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the acquisition, the insider directly owned 1,346,501 shares in the company, valued at $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.